211 related articles for article (PubMed ID: 24699253)
1. High-throughput screening for the identification of new therapeutic options for metastatic pheochromocytoma and paraganglioma.
Giubellino A; Shankavaram U; Bullova P; Schovanek J; Zhang Y; Shen M; Patel N; Elkahloun A; Lee MJ; Trepel J; Ferrer M; Pacak K
PLoS One; 2014; 9(4):e90458. PubMed ID: 24699253
[TBL] [Abstract][Full Text] [Related]
2. Current and future therapeutic approaches for metastatic pheochromocytoma and paraganglioma: focus on SDHB tumors.
Matro J; Giubellino A; Pacak K
Horm Metab Res; 2013 Feb; 45(2):147-53. PubMed ID: 23322515
[TBL] [Abstract][Full Text] [Related]
3. SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma.
Hadoux J; Favier J; Scoazec JY; Leboulleux S; Al Ghuzlan A; Caramella C; Déandreis D; Borget I; Loriot C; Chougnet C; Letouzé E; Young J; Amar L; Bertherat J; Libé R; Dumont F; Deschamps F; Schlumberger M; Gimenez-Roqueplo AP; Baudin E
Int J Cancer; 2014 Dec; 135(11):2711-20. PubMed ID: 24752622
[TBL] [Abstract][Full Text] [Related]
4. Personalized drug testing in human pheochromocytoma/paraganglioma primary cultures.
Wang K; Schütze I; Gulde S; Bechmann N; Richter S; Helm J; Lauseker M; Maurer J; Reul A; Spoettl G; Klink B; William D; Knösel T; Friemel J; Bihl M; Weber A; Fankhauser M; Schober L; Vetter D; Broglie Däppen M; Ziegler CG; Ullrich M; Pietzsch J; Bornstein SR; Lottspeich C; Kroiss M; Fassnacht M; Wenter VUJ; Ladurner R; Hantel C; Reincke M; Eisenhofer G; Grossman AB; Pacak K; Beuschlein F; Auernhammer CJ; Pellegata NS; Nölting S
Endocr Relat Cancer; 2022 May; 29(6):285-306. PubMed ID: 35324454
[TBL] [Abstract][Full Text] [Related]
5. Opposing effects of HIF1α and HIF2α on chromaffin cell phenotypic features and tumor cell proliferation: Insights from MYC-associated factor X.
Qin N; de Cubas AA; Garcia-Martin R; Richter S; Peitzsch M; Menschikowski M; Lenders JW; Timmers HJ; Mannelli M; Opocher G; Economopoulou M; Siegert G; Chavakis T; Pacak K; Robledo M; Eisenhofer G
Int J Cancer; 2014 Nov; 135(9):2054-64. PubMed ID: 24676840
[TBL] [Abstract][Full Text] [Related]
6. Temozolomide Is a Potential Therapeutic Tool for Patients With Metastatic Pheochromocytoma/Paraganglioma-Case Report and Review of the Literature.
Tong A; Li M; Cui Y; Ma X; Wang H; Li Y
Front Endocrinol (Lausanne); 2020; 11():61. PubMed ID: 32132978
[No Abstract] [Full Text] [Related]
7. Targeted molecular medicine: advances in the treatment of metastatic phaeochromocytoma and paraganglioma.
Naruse M; Young WF
Lancet; 2024 Mar; 403(10431):1001-1003. PubMed ID: 38402884
[No Abstract] [Full Text] [Related]
8. Cytocidal activities of topoisomerase 1 inhibitors and 5-azacytidine against pheochromocytoma/paraganglioma cells in primary human tumor cultures and mouse cell lines.
Powers JF; Korgaonkar PG; Fliedner S; Giubellino A; Pacak K; Sahagian GG; Tischler AS
PLoS One; 2014; 9(2):e87807. PubMed ID: 24516563
[TBL] [Abstract][Full Text] [Related]
9. Rationale and evidence for sunitinib in the treatment of malignant paraganglioma/pheochromocytoma.
Joshua AM; Ezzat S; Asa SL; Evans A; Broom R; Freeman M; Knox JJ
J Clin Endocrinol Metab; 2009 Jan; 94(1):5-9. PubMed ID: 19001511
[TBL] [Abstract][Full Text] [Related]
10. Metastatic pheochromocytoma/paraganglioma related to primary tumor development in childhood or adolescence: significant link to SDHB mutations.
King KS; Prodanov T; Kantorovich V; Fojo T; Hewitt JK; Zacharin M; Wesley R; Lodish M; Raygada M; Gimenez-Roqueplo AP; McCormack S; Eisenhofer G; Milosevic D; Kebebew E; Stratakis CA; Pacak K
J Clin Oncol; 2011 Nov; 29(31):4137-42. PubMed ID: 21969497
[TBL] [Abstract][Full Text] [Related]
11. Inhibitory Effect of the Noncamptothecin Topoisomerase I Inhibitor LMP-400 on Female Mice Models and Human Pheochromocytoma Cells.
Schovanek J; Bullova P; Tayem Y; Giubellino A; Wesley R; Lendvai N; Nölting S; Kopacek J; Frysak Z; Pommier Y; Kummar S; Pacak K
Endocrinology; 2015 Nov; 156(11):4094-104. PubMed ID: 26267380
[TBL] [Abstract][Full Text] [Related]
12. Niche for polyamine inhibition in treatment of metastatic pheochromocytoma and paraganglioma.
Ghayee HK; Hatch H; Bergeron RJ; Hadrava Vanova K; Pacak K; Tevosian S
Eur J Clin Invest; 2024 May; 54(5):e14162. PubMed ID: 38381501
[No Abstract] [Full Text] [Related]
13. Clinical features and outcomes of metastatic pheochromocytoma treated by cytotoxic chemotherapy.
Fujiwara Y; Ohmoto A; Fukuda N; Wang X; Urasaki T; Hayashi N; Sato Y; Nakano K; Yunokawa M; Ono M; Tomomatsu J; Yuasa T; Yonese J; Takahashi S
Endocr J; 2021 Jun; 68(6):671-681. PubMed ID: 33518616
[TBL] [Abstract][Full Text] [Related]
14. Modeling succinate dehydrogenase loss disorders in C. elegans through effects on hypoxia-inducible factor.
Braun MM; Damjanac T; Zhang Y; Chen C; Hu J; Maher LJ
PLoS One; 2019; 14(12):e0227033. PubMed ID: 31887185
[TBL] [Abstract][Full Text] [Related]
15. Bioinformatic analysis of differentially expressed genes as prognostic markers in pheochromocytoma and paraganglioma tumors.
Shi Z; Kong X; Li C; Liu H; Aliagan AI; Liu L; Shi Y; Shi X; Ma B; Jin R; Wang S; Pan D; Tang J
Genes Genet Syst; 2021 Jul; 96(2):55-69. PubMed ID: 34039789
[TBL] [Abstract][Full Text] [Related]
16. Targeting of mTORC2 may have advantages over selective targeting of mTORC1 in the treatment of malignant pheochromocytoma.
Zhang X; Wang X; Xu T; Zhong S; Shen Z
Tumour Biol; 2015 Jul; 36(7):5273-81. PubMed ID: 25666752
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy with cyclophosphamide, vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma: systematic review and meta-analysis.
Niemeijer ND; Alblas G; van Hulsteijn LT; Dekkers OM; Corssmit EP
Clin Endocrinol (Oxf); 2014 Nov; 81(5):642-51. PubMed ID: 25041164
[TBL] [Abstract][Full Text] [Related]
18. Antiangiogenic therapies for pheochromocytoma and paraganglioma.
Jimenez C; Fazeli S; Román-Gonzalez A
Endocr Relat Cancer; 2020 Jul; 27(7):R239-R254. PubMed ID: 32369773
[TBL] [Abstract][Full Text] [Related]
19. Transcriptome Analysis of lncRNAs in Pheochromocytomas and Paragangliomas.
Job S; Georges A; Burnichon N; Buffet A; Amar L; Bertherat J; Bouatia-Naji N; de Reyniès A; Drui D; Lussey-Lepoutre C; Favier J; Gimenez-Roqueplo AP; Castro-Vega LJ
J Clin Endocrinol Metab; 2020 Mar; 105(3):. PubMed ID: 31678991
[TBL] [Abstract][Full Text] [Related]
20. Hypoxia potentiates the cytotoxic effect of piperlongumine in pheochromocytoma models.
Bullova P; Cougnoux A; Abunimer L; Kopacek J; Pastorekova S; Pacak K
Oncotarget; 2016 Jun; 7(26):40531-40545. PubMed ID: 27244895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
